Jubilant Announces Drug Discovery Alliance in Neuroscience

By Jubilant Discovery Services Inc., PRNE
Monday, June 27, 2011

NOIDA, India, June 28, 2011 -


 

Jubilant Discovery Services Inc., Bedminster, New Jersey, a
Jubilant Life Sciences Company, announced today that it has
entered into a drug discovery alliance with Janssen Pharmaceutica
N.V., Beerse, Belgium, that will aim to deliver preclinical
candidates to Janssen.  The alliance is set to span an initial
period of 3 years and will focus on multiple targets in the
area of neuroscience.

Under the terms of the alliance agreement, Janssen will transfer
ongoing efforts on selected drug discovery targets to Jubilant.
Jubilant shall then carry out the research services and deliver
preclinical candidates to Janssen for possible further development
and commercialization.  In addition to receiving research
funding, Jubilant may also be eligible to receive milestones and
royalties should Janssen successfully develop and commercialize the
candidates.

Commenting on this development, Sri Mosur, CEO &
President, Global Drug Discovery & Development,
Jubilant
, said:  We are very pleased to
collaborate with Janssen, a world leader in pharmaceutical research
and commercialization. The collaboration
will utilize
Jubilant
s global research network to include our new
research facility in the
US focused in the area of
neuroscience, in addition to our India-based research centers. We
look forward to enhancing the research and development efforts at
Janssen through this unique and creative alliance in these dynamic
times in the industry
.

About Jubilant

Jubilant Discovery Services is New Jersey based US
subsidiary of Jubilant Biosys  Ltd, a Jubilant Life Sciences
Company. It will focus on providing Target Validation and Screening
solutions to its  global collaborators and more significantly
in real time for  the US based collaborators. The facility
will integrate its activities with R&D facilities of Jubilant
in India as well as of its  US collaborators to  support
Lead Generation and Target validation efforts. Staffed with
personnel with screening expertise, it will focus in areas of Ion
channels, EPHys and screening platforms in GPCR’s and Kinases.

Jubilant Life Sciences Limited is an integrated Pharma
and Life Sciences Company. It is the largest Custom Research and
Manufacturing Services (CRAMS) player and a leading Drug Discovery
and Development Solution (DDDS) provider out of India. The Company
provides Life Sciences products and services across the value
chain.  With 10 world-class manufacturing facilities and a
team of ~ 5700 multicultural people across the globe, the Company
is committed to deliver value to its customers spread across 70
countries.  The Company is well recognized as a ‘Partner of
Choice’ by leading life sciences companies worldwide.  

For more info: href="www.jubl.com">www.jubl.com  
 

Contact for Business Queries
href="mailto:narendra_kumar@jubilantbiosys.com">narendra_kumar@jubilantbiosys.com

+919611104886

.

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :